BCL2 and cancer: We are rapidly learning that sensitivity to senolytic BH3 mimetics is not necessarily an integral part of senescence and some TIS cancer cells—particularly those generated by non-genotoxic drugs—are refractory to the most studied broad-spectrum senolytic, the dual BCL-xL/BCL-2 inhibitor ABT-263/navitoclax [30–36].